NDA 20897, held by Janssen Pharms. Oxybutynin Chloride.
As of Nov 16, 2026, NDA 20897 (Ditropan Xl), held by Janssen Pharms, was first approved by FDA on Dec 16, 1998, with 23 approved supplements and 0 published complete response letters.
| Jun 30, 2004 | Supplement 13Efficacy (new indication or use) · Standard review | Approved | |
| Apr 15, 2003 | Supplement 9Efficacy (new indication or use) · Standard review | Approved | |
| Dec 16, 1998 | Original applicationNew dosage form · Standard review | Approved |
| Ditropan Xl5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · tablet, extended release;oral | Oxybutynin Chloride | DiscontinuedReference drug |
| Ditropan Xl10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · tablet, extended release;oral | Oxybutynin Chloride | DiscontinuedReference drug |
| Ditropan Xl15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · tablet, extended release;oral | Oxybutynin Chloride | DiscontinuedReference drug |
| Mar 29, 2021 | Supplement 38Labeling · Standard review | Approved | |
| Sep 12, 2019 | Supplement 37Labeling · Standard review | Approved | |
| Oct 26, 2018 | Supplement 36Labeling · Standard review | Approved | |
| Sep 13, 2016 | Supplement 35Labeling · Standard review | Approved | |
| Feb 27, 2015 | Supplement 33Labeling · Standard review | Approved | |
| Aug 1, 2013 | Supplement 32Labeling · Standard review | Approved | |
| Nov 13, 2012 | Supplement 31Labeling · Standard review | Approved | |
| Mar 23, 2012 | Supplement 30Labeling · Standard review | Approved | |
| Dec 15, 2011 | Supplement 29Labeling | Approved | |
| Jun 28, 2011 | Supplement 28Labeling | Approved | |
| Jul 13, 2009 | Supplement 24Labeling · Standard review | Approved | |
| Feb 6, 2008 | Supplement 18Labeling · Standard review | Approved | |
| Jun 30, 2004 | Supplement 13Efficacy (new indication or use) · Standard review | Approved | |
| Apr 15, 2003 | Supplement 10Labeling · Standard review | Approved | |
| Apr 15, 2003 | Supplement 9Efficacy (new indication or use) · Standard review | Approved | |
| Apr 17, 2000 | Supplement 8Labeling · Standard review | Approved | None posted |
| Sep 29, 1999 | Supplement 7Manufacturing · Standard review | Approved | None posted |
| Sep 28, 1999 | Supplement 5Manufacturing · Standard review | Approved | None posted |
| Jul 20, 1999 | Supplement 6Manufacturing · Standard review | Approved | None posted |
| Jun 30, 1999 | Supplement 4Manufacturing · Standard review | Approved | None posted |
| Jun 22, 1999 | Supplement 2Manufacturing · Standard review | Approved | |
| Jun 9, 1999 | Supplement 1Manufacturing · Standard review | Approved | None posted |
| May 25, 1999 | Supplement 3Manufacturing · Standard review | Approved | None posted |
| Dec 16, 1998 | Original applicationNew dosage form · Standard review | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters